Bibliometric analysis of research trends and emerging hotspots in plastic surgery publications
Chenhao Zhang , Qingxiong Yu , Tianyu Zhang
Plastic and Aesthetic Research ›› 2026, Vol. 13 ›› Issue (1) : 18
Aim: The field of plastic surgery has experienced substantial growth in annual publications over the past decades. A comprehensive analysis of global publication trends is needed to map the evolving research landscape and identify future directions.
Methods: A bibliometric analysis was conducted on publications affiliated with global plastic surgery institutions from 2001 to 2025, sourced from the PubMed database. Analyses of publication trends, geographic distributions, journal preferences, and research hotspots were performed using R (Bibliometrix) and CiteSpace.
Results: A total of 117,084 articles were identified, showing an 8.8-fold increase in annual publications from 2001 to 2025. China demonstrated the most rapid growth, with its share of global publications rising from 5.5% to 25.2%. Analysis of Journal Citation Reports (JCR) Q1 publications revealed similar growth, with China’s share increasing to 34.3% in 2025. Research hotspots have evolved from reconstructive techniques (e.g., perforator flaps) to molecular biology (e.g., nerve regeneration, targeted cancer therapy) and, most recently, artificial intelligence.
Conclusion: Plastic surgery research is dynamically evolving, characterized by increasing volume, a shifting global contribution led by China, and a transition towards molecular biology, regenerative medicine, and data science. Future efforts should focus on addressing methodological challenges and leveraging emerging technologies to advance personalized and regenerative treatments.
Plastic surgery / bibliometric analysis / visual analysis
| [1] |
2024 Plastic Surgery Statistics Report. Available from: https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf. [Last accessed on 15 Jun 2026]. |
| [2] |
ISAPS. Global survey 2024: full report and press releases. Available from: https://www.isaps.org/discover/about-isaps/global-statistics/global-survey-2024-full-report-and-press-releases/. [Last accessed on 15 Jun 2026]. |
| [3] |
Aesthetic Medicine Market (2026 - 2033). Available from: https://www.grandviewresearch.com/industry-analysis/medical-aesthetics-market. [Last accessed on 15 Jun 2026]. |
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
van Rooij JAF, Bijkerk E, van der Hulst RRJW, van Kuijk SMJ, Tuinder SMH. Replacing an implant-based with a DIEP flap breast reconstruction: breast sensation and quality of life.Plast Reconstr Surg2023;152:293-304 |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
Machiels JP, Haddad RI, Fayette J, et al.; LUX-H&N 1 investigators. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583-94. |
| [29] |
|
| [30] |
|
| [31] |
Burtness B, Harrington KJ, Greil R, et al.; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915-28. |
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
/
| 〈 |
|
〉 |